Skip to main content

Table 4 Correlation between prognostic factors and androgen concentrations in blood and prostate tissue*

From: High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients

 

Gleason score

Clinical stage

% positive cores

Parameter

≥8

≤7

p value

HR

95% CI

≥IV

≤III

p value

HR

95% CI

≥30%

<30%

p value

HR

95% CI

No. of patients

63

130

   

27

166

   

50

143

   

Median age (SD), years

73.0 (7.1)

69.5 (7.2)

0.076

1.050

0.995–1.108

75.0 (7.3)

70.0 (7.2)

0.255

1.049

0.966–1.138

73.0 (7.4)

70.0 (7.1)

0.120

1.052

0.987–1.121

Median serum PSA (95% CI), ng/mL

32.1 (69.2-216.2)

8.76 (12.3-20.2)

0.001

1.022

1.009–1.036

55.9 (113.4-435.8)

9.68 (16.5-27.9)

0.010

1.009

1.002–1.017

52.8 (83.6-262.0)

8.61 (9.6-24.8)

0.005

1.017

1.005–1.030

Median prostate volume, mL

27.0 (28.5-40.0)

27.9 (28.8-34.0)

0.387

0.991

0.970–1.012

33.2 (31.7-55.1)

27.5 (28.3-32.8)

0.057

1.024

0.999–1.049

28.4 (29.3-41.0)

27.6 (28.6-34.1)

0.164

0.982

0.957–1.007

Median concentration of T (95% CI) (blood) (/1000), pg/mL

3.11 (2.90-3.62)

3.64 (3.67-4.14)

0.012

0.706

0.538–0.926

3.21 (2.56-4.06)

3.61 (3.56-3.96)

0.354

0.839

0.579–1.216

3.12 (2.84-3.74)

3.66 (3.62-4.06)

0.113

0.78

0.575–1.060

Median concentration of DHT (95% CI) (tissue), pg/mg

5.31 (6.15-10.27)

7.31 (9.26-13.02)

0.222

0.974

0.935–1.016

4.68 (3.94-11.16)

7.28 (9.04-12.18)

0.756

0.992

0.942–1.044

5.26 (4.86-7.32)

7.58 (9.77-13.46)

0.003

0.878

0.806–0.956

Median concentration of T (95% CI) (tissue), pg/mg

0.90 (1.20-2.23)

0.46 (0.68-1.09)

0.041

1.388

1.013–1.900

2.03 (1.74-3.84)

0.50 (0.72-1.06)

0.002

1.713

1.227–2.391

1.03 (1.42-2.70)

0.47 (0.67-1.02)

0.001

2.432

1.425–4.148

  1. *Multivariate analysis by logistic regression. SD: Standard deviation; HR: Hazard ratio; CI: Confidence interval.